News

The company said that the cause of death and the relationship of the study drug, known as DAC:GRF, to the event, which occurred at a clinical site in

According to the companies, the current lack of clinical methods for definitive diagnosis remains a significant impediment for the management of Alzheimer’s patients, as well as for the

Forest and its Danish partner H. Lundbeck won the case against Ivax Corp, a subsidiary of Teva, after it applied to the FDA for approval to sell a

The trial is being sponsored by the National Cancer Institute (NCI) under a clinical trials agreement with CuraGen for PXD101. The phase I portion of the study aims

The Swiss drug maker has also declared its offer for the UK biopharmaceutical company unconditional in all respects. This will allow for the delisting of NeuTec’s shares and

The jury found that Merck had acted responsibly in informing the medical community about the benefits and risks of the osteoporosis drug that was voluntarily withdrawn from the

The resubmission of the new drug application (NDA) addresses deficiencies in the original application outlined by the FDA in a non-approvable letter in August 2002. The FDA has

On May 27, 2005, Abraxis entered into a license agreement with Taiho, a subsidiary of Otsuka Pharmaceutical, under which Abraxis granted Taiho the exclusive rights to market and

Epix said following Berlin-based Schering’s decision not to exercise its option it will retain full rights to the EP-2104R program. Schering is in the process of being acquired